Related Experiment Video
Updated: Sep 3, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection
Teruhiko Imamura1, Toshihide Izumida1, Masakazu Hori1
1The Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
Insights
Wild-type cardiac amyloidosis with systolic dysfunction improved with tafamidis and neurohormonal blockers. This combination therapy shows promise for cardiac reverse remodeling in affected patients.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Amyloidosis Research
Background:
- Cardiac amyloidosis typically causes diastolic dysfunction, but systolic dysfunction can occur in advanced stages.
- Effective therapeutic strategies for cardiac amyloidosis with systolic dysfunction are not well-established.
- Wild-type cardiac amyloidosis is an increasingly recognized cause of heart failure.
Observation:
- A 77-year-old male patient presented with wild-type cardiac amyloidosis and severe systolic dysfunction (left ventricular ejection fraction 27%).
- The patient received a 6-month treatment regimen including tafamidis (80 mg) and standard neurohormonal blockers (carvedilol, enalapril, spironolactone).
Findings:
- The combined therapy led to a significant improvement in left ventricular ejection fraction, increasing from 27% to 55%.
- This suggests a positive response to tafamidis in conjunction with neurohormonal blockade.
Implications:
- Tafamidis combined with neurohormonal blockers may represent a novel therapeutic approach for cardiac amyloidosis.
- This strategy could facilitate cardiac reverse remodeling and improve systolic function in patients with this condition.
- Further research is warranted to validate these findings in larger patient cohorts.
Abstract:
Cardiac amyloidosis usually presents with diastolic dysfunction, but sometimes systolic dysfunction develops, particularly at its advanced stage. However, the therapeutic strategy for patients with cardiac amyloidosis and systolic dysfunction remains unknown. We report a 77-year-old man who was diagnosed with wild-type cardiac amyloidosis and systolic dysfunction with a left ventricular ejection fraction of 27%. Following 6-month medical therapy of tafamidis 80 mg and neurohormonal blockers (carvedilol 5.0 mg, enalapril 2.5 mg, and spironolactone 25 mg), the left ventricular ejection fraction improved to 55%. Tafamidis-incorporated neurohormonal blocker therapy might be a promising strategy to facilitate cardiac reverse remodeling in patients with cardiac amyloidosis and systolic dysfunction.
More Related Videos
11:51Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014